New hope for cancer patients with low immune cells: expanded access program launches
NCT ID NCT06956547
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 20 times
Summary
This expanded access program provides nogapendekin-alfa inbakicept to adults with lymphopenia (low white blood cell counts) caused by chemotherapy, immunotherapy, or radiation therapy. It is for patients who cannot join a clinical trial. The goal is to restore and maintain healthy lymphocyte levels to help the immune system recover.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon - Shiong Institute for Medicine
AVAILABLEEl Segundo, California, 90245, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.